- Home
- NZF vs GH Comparison
NZF vs GH Comparison
Compare NZF & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NZF
- GH
- Stock Information
- Founded
- NZF 2001
- GH 2011
- Country
- NZF United States
- GH United States
- Employees
- NZF N/A
- GH N/A
- Industry
- NZF Finance Companies
- GH Medical Specialities
- Sector
- NZF Finance
- GH Health Care
- Exchange
- NZF Nasdaq
- GH Nasdaq
- Market Cap
- NZF 2.5B
- GH 2.7B
- IPO Year
- NZF N/A
- GH 2018
- Fundamental
- Price
- NZF $12.89
- GH $20.68
- Analyst Decision
- NZF
- GH Strong Buy
- Analyst Count
- NZF 0
- GH 16
- Target Price
- NZF N/A
- GH $39.67
- AVG Volume (30 Days)
- NZF 496.8K
- GH 1.6M
- Earning Date
- NZF 01-01-0001
- GH 11-06-2024
- Dividend Yield
- NZF 4.67%
- GH N/A
- EPS Growth
- NZF N/A
- GH N/A
- EPS
- NZF N/A
- GH N/A
- Revenue
- NZF N/A
- GH $643,810,000.00
- Revenue This Year
- NZF N/A
- GH $27.01
- Revenue Next Year
- NZF N/A
- GH $18.30
- P/E Ratio
- NZF N/A
- GH N/A
- Revenue Growth
- NZF N/A
- GH 26.20
- 52 Week Low
- NZF $9.82
- GH $15.81
- 52 Week High
- NZF $12.29
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- NZF 47.21
- GH 33.92
- Support Level
- NZF $12.82
- GH $20.36
- Resistance Level
- NZF $12.97
- GH $21.95
- Average True Range (ATR)
- NZF 0.08
- GH 0.74
- MACD
- NZF -0.02
- GH 0.11
- Stochastic Oscillator
- NZF 15.48
- GH 16.56
About NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.